---
figid: PMC9257957__etm-24-02-11441-g02
pmcid: PMC9257957
image_filename: etm-24-02-11441-g02.jpg
figure_link: /pmc/articles/PMC9257957/figure/f3-ETM-24-2-11441/
number: Figure 3
figure_title: ''
caption: Bcr/Abl (Phospho-Tyr412) levels in (A) K562 and (B) R-K562 cells incubated
  with 100 µM IM, 2,500 nM Das, 100 ng/ml LPS, 10 ng/ml TNF and/or 50 µg/ml Verb for
  48 h. *P<0.05 untreated control cells vs. cells treated with IM, Das, LPS, TNF and/or
  Verb, **P<0.05 TNF vs. TNF + Verb; ∆P0.05 Verb vs. IM + Verb, Das + Verb and TNF
  + Verb (n=5). IM, imatinib; Das, dasatinib; LPS, lipopolysaccharide; TNF, tumor
  necrosis factor α; Verb, verbascoside.
article_title: Verbascoside potentiates the effect of tyrosine kinase inhibitors on
  the induction of apoptosis and oxidative stress via the Abl-mediated MAPK signalling
  pathway in chronic myeloid leukaemia.
citation: Gulsum Akgun-Cagliyan, et al. Exp Ther Med. 2022 Aug;24(2):514.
year: '2022'

doi: 10.3892/etm.2022.11441
journal_title: Experimental and Therapeutic Medicine
journal_nlm_ta: Exp Ther Med
publisher_name: D.A. Spandidos

keywords:
- chronic myeloid leukaemia
- imatinib
- dasatinib
- verbascoside
- MAPK
- Abl (Phospho-Tyr412)

---
